Cytokines and Chemokines in Erythema Migrans

University Medical Centre Ljubljana

Status: Unknown

Conditions: Erythema Migrans

Treatments: Drug: antibiotic treatment

Study type: Interventional

Funder types: Other

Identifiers

NCT02147249

EM-0613

Details and patient eligibility

About

The main objective of this study is to characterize the inflammatory proteins, gene polymorphisms, and transcriptome profiles in patients with erythema migrans to gain better insight into pathogenesis of early Lyme borreliosis and to define new immune modulators that could serve as biomarkers of disease activity.

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• erythema migrans in patients > 18 years

Exclusion criteria

• pregnancy or lactation
• taking antibiotic with antiborrelial activity within 10 days

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

150 participants in 1 patient group

erythema migrans patients treated with antibiotics

Experimental group

Description:

adult patients with erythema migrans will be treated with oral antibiotics

Treatment:

Drug: antibiotic treatment